Beta Bionics (BBNX) Fundamental Analysis: Revenue, Earnings & Valuation

0.80 / 10

Underperform

Fundamental analysis rates the stock as underperform with a 0.8/10 score. Profit‑MV and Revenue‑MV are relatively strong, but cash‑MV, profit margins and ROA are negative, leading to a guarded outlook.

Analysis Checks(2/10)

Revenue-MV

Value-1.73

Score2/3

Weight-14.80%

1M Return1.21%

ROA (%)

Value-30.60

Score1/3

Weight9.72%

1M Return-0.82%

Net cash flow from operating activities / Operating revenue (%)

Value-50.80

Score1/3

Weight15.33%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-44.05%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-30.60

Score1/3

Weight9.72%

1M Return-0.82%

EBIT / Total operating revenue (%)

Value-83.92

Score1/3

Weight8.67%

1M Return-0.83%

Asset-MV

Value-0.55

Score1/3

Weight-4.70%

1M Return0.38%

Net profit / Total operating revenue (%)

Value-73.02

Score0/3

Weight52.58%

1M Return-6.68%

Cash-MV

Value0.02

Score1/3

Weight41.75%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight25.79%

1M Return-2.39%

Is BBNX fundamentally strong?

BBNX scores 0.80/10 on fundamentals and holds a Premium valuation at present. Backed by its -40.26% ROE, -73.02% net margin, -6.07 P/E ratio, 1.54 P/B ratio, and 78.95% earnings growth, these metrics solidify its Underperform investment rating.